Factors impacting survival after transarterial radioembolization in patients with hepatocellular carcinoma: Results from the prospective CIRT study.
JHEP Rep
; 5(2): 100633, 2023 Feb.
Article
em En
| MEDLINE
| ID: mdl-36593888
ALBI, albumin-bilirubin; BCLC, Barcelona Clinic Liver Cancer; BSA, body surface area; CIRSE, Cardiovascular and Interventional Radiological Society of Europe; CIRT, CIRSE Registry for SIR-Spheres Therapy; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; HR, hazard ratio; INR, international normalized ratio; IPTW, inverse probability of treatment weighting; OS, overall survival; PFS, progression-free survival; PVT, portal vein thrombosis; REILD, radioembolization-induced liver disease; SIRT; TACE, transcatheter arterial chemoembolization; TARE, transarterial radioembolization; Y90, Yttrium-90; dosimetry; hPFS, hepatic progression-free survival; liver; mBSA, modified body surface area; observational; radioembolization; registry
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article